GSK vs. INCY: GSK vs. Incyte Stock Comparison

Company Profile

GSK (GSK) and Incyte (INCY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but GSK is classified in Pharmaceuticals while INCY is classified in Biotechnology.

Incyte (INCY) trades as ordinary local shares, while GSK (GSK) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both GSK (GSK) at 28.27% and Incyte (INCY) at 7.84% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

For every dollar of sales, both GSK (GSK) at 12.97% and Incyte (INCY) at 6.71% retain more as net profit than most peers, landing in the top net margin quartile of their industries.

Both GSK (GSK) at 32.14% and Incyte (INCY) at 33.72% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both GSK (GSK) at 4.11% and Incyte (INCY) at 21.22% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Both companies show strong earnings momentum, but Incyte (INCY) at 4,173.33% is the standout with EPS growth above its industry range; GSK (GSK) at 123.15% also sits in the top quartile.

Growth Metrics

Financial Strength

Incyte (INCY) at 3.84 keeps current ratio within its industry’s typical mid-range, while GSK (GSK) at 0.86 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for GSK.

Incyte (INCY) at 0.01 keeps leverage in the lower quartile, while GSK (GSK) at 1.30 sits in the higher-leverage quartile.

Financial Strength Metrics

Dividends

Incyte (INCY) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile GSK (GSK) reports a yield of 1.57%, ranking against industry peers normally.

Incyte (INCY) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile GSK (GSK) reports a payout of 63.33%, ranking against industry peers normally.

Dividend Metrics

Valuation

GSK (GSK) at 17.54 is near its industry’s usual P/E ratio, while Incyte (INCY) at 61.05 sits in the richer quartile — INCY needs stronger growth or earnings quality to justify the premium.

GSK (GSK) at 3.01 sits in the cheaper P/S ratio quartile while Incyte (INCY) at 4.06 prices around its industry’s middle — GSK costs less per dollar of sales, though read it alongside growth and margins.

On P/B ratio, both GSK (GSK) at 4.02 and Incyte (INCY) at 4.33 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics